Algeta ASA

Pharmaceutical Manufacturing • Oslo, Oslo, Norway • 11-20 Employees

Company overview

Headquarters	Oslo, Oslo, Norway
Phone number	+4723007990
Website	algeta.com
NAICS	3254
Founded	1997
Employees	11-20
Socials

Key Contacts at Algeta ASA

Berit Øien Harr

Director Clinical Production And Supply

Bente Jarvaag

Director Hr

Jan Børge Jakobsen

Director Commercial Productions

Ingvild Haugen

Director Clinical Research

Algeta ASA Email Formats

Algeta ASA uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	42.1%
{first name}@company.com	john@company.com	25.3%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	14.8%
{first name}{last name}@company.com	johndoe@company.com	10.2%
{last name}@company.com	doe@company.com	7.6%

About Algeta ASA

March 6th The Bayer Group completed the voluntary takeover offer for Norwegian pharmaceutical company Algeta ASA, Oslo. As a result, Bayer now holds 98.2 % of the shares and voting rights in Algeta. Bayer intends to initiate a compulsory acquisition process in order to acquire the remaining shares of minority shareholders in Algeta in the coming days. Bayer intends to file for delisting of the Algeta shares from the Oslo Stock Exchange (OSE). Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. Algeta's lead product Xofigo® injection (radium Ra 223 dichloride, radium-223; previously called Alpharadin) is an alpha particle-emitting pharmaceutical with an anti-tumor effect on bone metastases. In September 2009, Algeta signed an agreement with Bayer for the development and commercialization of Xofigo. Under the terms of this agreement, Bayer will develop, apply for health authority approvals worldwide and commercialize Xofigo globally. Algeta is eligible for royalties and milestones based on Bayer’s sales of Xofigo outside the US, and Algeta US is co-promoting Xofigo with Bayer in the US. Algeta is also evaluating the potential of Targeted Thorium Conjugates (TTCs), which are based on conjugating the alpha-emitter thorium-227 to targeting molecules, as a basis of a potential future pipeline of tumor-targeting alpha-pharmaceutical candidates. In December 2013, the Board of Directors of Algeta ASA announced that it had unanimously recommended the voluntary cash offer (the “Offer”) of NOK 362 per share from Bayer to acquire the entire issued share capital of Algeta.

Algeta ASA revenue & valuation

Annual revenue	$1,368,880
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$4,400,000
Total funding	No funding

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Entry

Director

C-Suite

Employees by Department

Algeta ASA has 11 employees across 6 departments.

Departments

Number of employees

Funding Data

Algeta ASA has never raised funding before.

Frequently asked questions

Algeta ASA is located in Oslo, Oslo, NO.

You can reach Algeta ASA at +4723007990.

Algeta ASA was founded in 1997, making it 29 years old. The company has established itself as a significant player in its industry over this time.

Algeta ASA has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.